Corporate Profile
To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Jan 05, 2023
Dec 14, 2022
Events
Jan 12, 2023 from 10:30 AM to 11:10 AM PST
Jun 8, 2022 at 3:30 PM EDT